Drugs / CLG561
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01835015 | May 2013 → Nov 2014 | age-related macular degeneration | Alcon Research | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT02515942 | Sep 2015 → Aug 2017 | diffuse secondary choroid atrophy | Alcon Research | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLG561 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02515942 ↗ |
| Route | Intravitreal | “Administered by intravitreal injection, Day 1” NCT01835015 ↗ |